DECEMBER 2012 n VSM
34
ureFlap’s Microchip Pet Door has been specially designed for small dogs and larger cats, with
hundreds of advance orders placed before it was launched at the recent London Vet Show. The company has found that pet owners are particu- larly receptive to purchasing SureFlap products from their vet as it helps to reduce stress by restricting access to intruders.
According to the manufacturer,
reliability is a key feature of SureFlap products. The new door has been built out of a curved polycarbonate and strong
hinges to withstand the attentions of the most persistent would-be intruder. Two independently sprung locks prevent the door twisting even when an intruder pushes hard against one corner, which is a common tactic, and double magnets hold the door securely in place. SureFlap’s microchip
reader,
located within the tunnel, has also been improved for the larger pet door. The pet door also incorporates new features such as the curfew mode, which allows pet owners to specify the times at which the door is locked or open; ideal for keeping a pet indoors overnight. The settings are
New Florfenicol Antibiotic Launched
new antibiotic has been un- veiled by Norbrook Labora- tories for use in the treat- ment of pneumonia. Norfenicol Solution for injection is a broad spectrum antibiotic licensed for the treatment of both cattle and pigs.
A Norbrook’s GB veterinary
www.vetsuppliesmag.com
Microchip Pet Door for Big Cats and Small Dogs S
controlled like an alarm clock and shown on an integral display screen at the top of the product. The SureFlap Microchip Pet Door is compatible with all international formats of identification microchip, including all 15 digit (FDXB), 10 digit (FDXA & Trovan Unique), and nine digit (AVID-encrypted) microchips.
It also works well with the
recently introduced mini microchips. SureFlap
t. +44 (0)1954 211664
e.
trade@sureflap.co.uk w.
www.sureflap.co.uk
LARGE ANIMAL
New Ultrasound System by BCF
advisor
Barry McInerney said to VSM: “With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK, costing the agricultural industry an estimated £80m per year.” Norfenicol
is indicated for
the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
Norbrook Laboratories t. +44 (0)28 3026 4435
e.
customer.services@
norbrook.co.uk w.
www.norbrook.com
pany BCF Technology has announced the launch of the new Logiq S7 expert ultra- sound system.
V The new system is said
to offer the latest in ultrasound technology and offers a significant leap forward in imaging capability. The system offers specialised features such as B-Flow, elastography, flow quantification, contrast imaging, B-Steer+, 3D/4D ultrasound, volume imaging, and multi-modality imaging display. Practices such as O’Gorman,
Slater, Main & Partners, and Newmarket Equine Hospital have already invested in the system.
BCF Technology t. +44 (0)1506 460 023
e.
info@bcftechnology.com w.
www.bcftechnology.com
SMALL ANIMAL
GENERAL
eterinary imaging
com-
Treatment of Equine Cushings Disease
rascend® is the first li- censed medicine for the treatment of clinical signs associated with PPID in horses (Equine Cushing’s Disease). Prascend® contains a medi-
P
cine called pergolide, which acts directly on the dopamine-produc- ing neurons in the hypothalamus, helping to bring cortisol concentra- tions in the bloodstream back to nor- mal levels.
Prascend® is normally given
once daily, and can be mixed with a small volume of molasses or food to ease administration, or alternatively by dissolving in a small volume of water and administering directly into the mouth. Tablets should not be crushed.
As Prascend® affects cortisol
production, there is usually a short lag between beginning treatment (re- ducing cortisol production) and see- ing a horse return to normal in terms
of clinical signs (as levels of cortisol in the body become normal again). It can take up to 6-12 weeks to see the full benefit of treatment.
Boehringer Ingelheim t. +44 (0)1344 424600 e. communications@
bra.boehringer-ingelheim.com
w.
www.boehringer-ingelheim.co.uk/ Products/
animalhealth.html
EQUINE
Web-Based Viewer D
icomPACS has launched a mobile viewer that offers physicians and nursing care staff mobile freedom not only when working in a clinic or practice but anywhere and anytime, operating on platform- independent viewing. The viewer is de- signed both for mobile ter- minals like the iPad as well as for network PCs. Mobile use is as intuitive as using an app.
According to the
manufacturer, no matter whether you use Internet Explorer, Moz- illa Firefox, or Google Chrome, dicomPACS®MobileView works in- dependently of the browser. Modern streaming technology guarantees fast uploading of images. Mobile devices even include generally established image view- ing functions. Images can be com- pared by selecting different grids, and
GENERAL
brightness is adjustable.
Enlarging
or reducing images as well as rotat- ing and mirroring is easy. Scrolling through image series and cineloop in multiframe series and CT/MRT is also possible. Thanks to user-friendly multi-touch operation, functions can be accessed quickly.
DicomPACS t. +49 381 36 600 500
e.
info@or-technology.com w.
www.or-technology.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44